INTRODUCTION
Biological sciences rely on modeling systems to help conceptualize, understand, test and predict the physiological and pathophysiological pheno mena being studied. These modeling strategies are rich and diverse, and include not only in vitro and in vivo approaches, but also theoretical or in silico techniques. Mathematical and compu tational cancer modeling have recently gained momentum thanks to a combination of related factors. Such factors include the advent of systemsbiologydriven concepts in biomedicine that draw from an ever increasing volume of molecular data, [1] [2] [3] [4] [5] the introduction of novel and cancerfocused interdisciplinary funding pro grams at the NIH-such as the Integrative Cancer Biology Program 6 -and the decreasing cost of the computational power necessary to run large and clinically relevant simulations. In silico models, such as the mathematical, continuum-discrete hybrid model by Anderson et al. 7 for studying the microscopic interaction of a virtual tumor with its microenvironment, are a good example of an interdisciplinary approach within the broad bio medical community. Other prominent theory inspired approaches to tumorigenesis include the application of game theory, [8] [9] [10] scaling laws, 11, 12 fractals [13] [14] [15] and graph theory, 16 to name only a few. Given the emergence of these strategies and other methods and techniques, cancerrelated topics of interest for applied mathematicians and biophysicists now go beyond the classic domains of volumetric tumor growth dynamics 17, 18 and vascularization patterns. [19] [20] [21] [22] These techniques can now be applied to investigate genetic instability 23 and mutagenesis, 24 for instance, as well as the com plexity of tumor-immune system interaction. 25, 26 A description of the entire field of in silico cancer research is beyond the scope of this Review. We have chosen to exemplify the development of modeling in clinical oncology by reviewing selected studies on modeling the progression and therapy of highly malignant brain tumors. We briefly discuss the current limitations, as well as the potential applications, of in silico cancer modeling.
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IN SILICO MODeLING OF BRAIN TUMORS
Over the past decade, modeling of malignant brain tumors has become popular in the in silico research field, for several reasons. Firstly, despite all efforts, the outcome of patients with high grade astrocytomas or gliomas (most notably glioblastoma multiforme; GBM) remains grim and, therefore, innovative treatment approaches are desperately needed. Secondly, brain tumors grow within a biologically contained environ ment; that is, they tend not to metastasize outside the central nervous system, and thus seem to pose a more circumscribed and, from a biomechanistic modeling perspective, more approachable problem than other types of malignancy. Thirdly, although the countless experimental and clinical studies conducted have undoubtedly advanced our understanding of the molecular and microscopic characteris tics of brain tumors, we are often left with too few clues as to how to connect the many data 'dots' in order to construct a complete picture of tumorigenesis. Powerful integrative platforms are required, therefore, to capture the complex dynamics of tumors at all levels of organization (i.e. molecular, cellular, and organism). 27 As such, the pathogenesis and pathophysiology of brain tumors provide an ideal target for computational and mathematical methods and techniques.
A considerable body of in silico work has focused on developing a better understanding of glioma growth through the use of mathema tical models that focus on data derived from in vitro growth studies. More than three decades ago, Greenspan 28,29 put forward two impor tant yet generic and rather simplified assump tions: that the geometry of a microscopic tumor remains spherical at all times; and that the inter nal core of a tumor turns necrotic. Followup work by Chaplain and Sleeman 30 introduced biomechanical principles, including elasticity, to describe the mechanical interactions between tissue and the expanding microscopic tumor. The authors modeled the material composition of a solid tumor using a strain energy func tion, attempting to deduce a basic mathematical description of the processes involved in cancer grading and staging from the in silico results of simulating solid tumor growth in conjunc tion with aspects of surface morphogenesis. Greenspan's seminal work also provided the foundation for a brain tumor model developed by Zheng and colleagues, 31 which was devel oped by using a multiscale hybrid computer simulator to investigate the mechanisms of cancer infiltration on the basis of in vitro data (Box 1).
More recently, Khain and Sander 32 presented a model of invasive glioma that used two coupled reaction-diffusion equations to study growth instabilities and the resulting growth patterns that emerged in vitro. In addition, Frieboes et al. 33 studied in vitro and in silico the growth and shape of human gliomas as a function of oxygen, nutri ent and growth factor concentrations, and of cell adhesion forces. The authors used a finite element method to solve a set of nonlinear differential equations in order to build up a twodimensional spatial tumor mass model that described growth dynamics and morphological changes. On the basis of their results, the authors proposed that the instability of tumor morphologies, which leads to tumor invasion, is quantitatively related to spatial variations in molecularlevel diffusions. Since brain tissue can be described as a nonlinear viscoelastic solid, 34 if one assumes displacement and strain are small, this is often an insufficient approximation of the actual tissue response. A finite element analysis is, therefore, commonly used to reduce the complicated mechanical prob lem to a more simplified matrix equation. [35] [36] [37] Although cancer models retain some level of validity for tumors cultured in vitro, in reality tumors tend not to grow in a strictly spherical 
Continuum model
Continuum models use a set of differential equations to describe variables such as change in tumor cell density, chemoattractant diffusion, and even kinetic molecular pathway networks.
Cellular automaton
A cellular automaton (CA) describes a spatial matrix in which the dynamics among neighboring 'nodes' are defined by a set of local interaction rules, which can also decide the transition and communication among the grid points.
discrete model A discrete model is often comprised of several states and a number of transitions, and is commonly represented by a CA.
Hybrid approach
Hybrid approaches combine both continuum and discrete techniques in one form or another. 34 presented an integrated, uni versal framework to predict the direction and extent of the spread of a primary brain tumor, with respect to time. This tumor growth model was developed using a nonlinear finite element method and with several clinical applications in mind, ranging from tumor boundary prediction and delineation to growth pattern research, diag nostic decision support, and radiotherapy plan ning. A number of mathematical continuum models (Box 1) have been developed for the same clinical applications, [38] [39] [40] [41] and are based largely on clinical imaging data such as serial CT scans or, more recently, on nuclear magnetic resonance (NMR) images. These studies use, in one form or another, reaction-diffusion equations of the type detailed in Equation 1 .
Agent-based modeling
Here, c represents cell density, D • 2 c stands for the diffusion capabilities of cells, r • c is growth, and m • c and K(t) • c describe cell loss due to mutation and treatment, respectively. 41 The results of the models that were developed using these equations support the following con cepts put forward by Woodward and colleagues: 41 first, that gliomas infiltrate so diffusely that they cannot be cured by surgery alone; second, that the more extensive a resection, the greater the life expectancy; and third, that measurement of growth and diffusion rates might facilitate better prediction of survival rates than the current histologybased system of grading gliomas. [42] [43] [44] A considerable shortcoming of all these models is that although they can grossly estimate the boundaries of the cortical and ventricular sur faces of the brain, they cannot account for the spatial heterogeneity of brain tissue with respect to grey and white matter.
In an attempt to overcome this limitation, Swanson et al. 45 presented a mathematical glioma model based on proliferation and diffusion rates that incorporated the differential effects of aug mented cell motility on white matter compared with grey matter, which in turn permitted the simulation of asymmetric nonspherical tumor geometries. The authors subsequently revised their model 46 so that they could quantify in three dimensions (3D) spatiotemporal growth and invasion of gliomas throughout a virtual human brain, in an effort to predict sites of potential tumor recurrence. The simulation results showed good agreement with clinically observed glioma progression patterns, as determined by CT scan ning. Clatz and coauthors 35, 36 also developed a set of 3D in vivo models based on clinical NMR images, which employed a finite element method to simulate the invasion of a GBM into the brain parenchyma and its mechanical interaction with the invaded structure. The algorithm by Clatz and coauthors 35 relied on diffusion tensor NMR imaging to account for anisotropic cell dif fusion along white matter tracts. The reactiondiffusion equation used to model tumor growth was coupled with the mechanical constitutive equation used to simulate the tumor's concomi tant mass effect; that is, the mechanical reaction of the parenchyma to the tumor's expansion. The authors compared simulation results produced by this algorithm with glioma growth observed on two consecutive NMR imaging data sets from a patient with a brain tumor, and noted a good correlation between modeling results and imaging data.
Despite their unquestionable merits, the above reviewed models describe glioma growth only as evolution of local tumorcell density at a com parably macroscopic scale. Moreover, the models rely on reaction-diffusion equations to account for tumor propagation; continuum approaches inevitably fail to capture the discrete nature of an individual cell's activity, let alone that of a single subcellular protein. More generally, the shortcomings of employing a continuum frame work to model tumor angiogenesis have already been highlighted by Orme and Chaplain. 47 To address the limitations of previous models, Kansal et al. 48, 49 introduced a discrete cellular automaton (CA; Box 1) 50 in an attempt to model Gompertzian GBM growth in tumor radius, over nearly three orders of magnitude, with only the following four microscopic parameters: the celldoubling time; the nutritional needs of growtharrested cells; the nutritional needs of proliferating cells; and the effects of mechanical confinement.
Nonetheless, these CA models fell short of investigating relevant fluid physical aspects. Neither a true continuum model nor a discrete model can fully describe the cancer system under investigation; therefore, hybrid approaches (Box 1)-including the socalled agentbased ∆ ∆ r e v i e w modeling (ABM) technique (Box 1), which encompasses both continuum and discrete modeling methods-have gained popularity. In particular, the capacity of the ABM technique to simulate tumor properties across multiple scales in space and time lends the method to study ing highly malignant brain tumors. 51 Mansury et al. 52, 53 developed a set of twodimensional brain cancer models, which simulated glioma cell proliferation, migration, quiescence and apoptosis on a microscopic scale by using a dis crete module, and distribution and diffusion of chemoattractants on a multicellular scale with a continuum module. Furthermore, Mansury and Deisboeck 52 introduced a chemotactic 'search precision' element (Equation 2) to represent the effect of cellsignal processing accuracy on the motility of glioma cells along the micro environmental path of "least resistance, most permission and highest attraction". 51
Here, T j denotes the attractiveness of location j, L j is the errorfree evaluation of location j, and
is an error term that is normally distributed with mean µ and variance σ. The parameter Ψ takes on a positive value between zero and one and represents the extent of search precision.
Athale et al. 54, 55 expanded this 'microscopicmacroscopic' approach by including the all important molecular scale in the form of a simplified representation of the EGFR pathway, which has a crucial role in glioma progression 56 and could be of considerable importance for therapeutic outcome. 57 In this method, each molecule comprising the EGFR pathway is rep resented by an equation of the kind described in Equation 3 .
Here, X i is the mass of i th (i = 1 -14 th ) molecules of the implemented EGFR signaling network, and α i and β i are the rate of synthesis and degradation of a given pathway molecule, respectively.
In this model, the protein phospholipase Cgamma downstream of EGFR is employed to 'decide' a cell's phenotype, in contrast to previous works that used a probability module to deter mine a cell's phenotype. Using this novel design, Athale et al. 54 described how the molecular profile of each individual glioma cell affects the cell's phenotypic switch, and how such single cell decisions can potentially affect the dynam ics of the entire tumor system. In a followup study, 55 the authors then demonstrated that increasing the EGFR density per cell results in acceleration of the entire tumor system's spatiotemporal expansion dynamics.
Zhang et al. 58 extended this work by presenting a 3D, multiscale, agentbased brain tumor model (Figure 1 ), which integrated an implicit mitogen activated protein kinase module, 59 as well as a cellcycle description, at the subcellular scale that was defined by Alarcon et al. 60 (Figure 2 ). This study also included a more complicated extra cellular matrix representation at the microscopic scale and investigated how molecular perturba tions migrate across scales in space and time. This work has triggered multicenter specific experi mental research that might lead to the discovery of interesting therapeutic targets, illustrating how modeling can serve as a hypothesisgenerating tool that can be explored in an experimental laboratory and, eventually, in clinics. Conversely, models can confirm and expand clinical observa tions; for example, Frieboes et al. 61 recently presented a novel predictive 3D algorithm that was based on firstprinciple reaction-diffusion equations. The model accounted for a variety of diffusive substrates and processes that appear within the context of micromacro func tional relationships. The work of these authors has facilitated the correlation of brain tumor morphology to growth, via quantification of the 
PRACTICAL APPLICATIONS OF IN SILICO MODeLING Chemotherapy
Theoretical modeling has already been applied clinically, particularly with regards to simulating the effect of radiotherapy and chemotherapy on tumor growth. This application is very relevant, as both modalities are standard components of conventional adjuvant treatment protocols that are implemented after surgical resection of highgrade gliomas. Other than Woodward and coworkers 41 who simulated brain tumor growth and infiltration following various extents of surgical resection, Tracqui et al. 40 developed a basic mathematical algorithm that modeled the changes in glioma density-c(x,t)-at location x and time t, in order to describe a tumor's sensiti vity to various chemotherapy regimens. As input data, the authors used eight serial CT scans taken over the course of 12 months from a patient with recurrence of anaplastic astrocytoma (i.e. 3 years after diagnosis and initial radiotherapy). The patient's treatment consisted of five cycles of six cytotoxic drugs (6thioguanine, procarbazine, dibromodulcitol, CCNN, 5fluorouracil, and hydroxyurea; given over 15 days, repeated every 6-8 weeks), and two cycles of cisplatin and neutron beam irradiation. An optimization algorithm that minimizes the error between simu lated tumor area and glioma area on CT deter mined the best fit of the model's six unknown parameters, which included proliferation rate and celldiffusion coefficients. Overall, there was good agreement between the clinical data and Negative feedback
r e v i e w the authors' algorithm, which also showed that a chemoresistant tumor subpopulation that emerged at a later stage during chemotherapy was capable of causing treatment failure. 40 Building on this work, Swanson et al. 62 devel oped a similar continuum model, but also con sidered the effect that the brain's known vascular heterogeneity might have on delivery and effi cacy of chemotherapy. Bearing in mind the fact that grey matter is more vascularized than white matter and that glioma cell motility is higher in white matter, it seems logical to assume that cancer cells would spend more time in grey matter regions and thus be exposed for longer periods to higher levels of chemotherapy. The authors tested this concept of underlying tissue heterogeneity by setting up a periodic region distribution pattern and then simulating expan sion, chemotherapy and recurrence of a high grade glioma in the frontoparietal region of the brain. Comparison of this model with real NMR imaging patterns from a patient with glioma who was treated with the receptor tyrosine kinase inhibitor imatinib mesylate indicated that the grey matter portion of a tumor might indeed be more accessible to chemotherapy than the white matter portion, whereas tumor progression is likely to continue in adjacent white matter areas that have already been infiltrated.
Another mathematical approach, which acts as an extension of the model presented by Frieboes and colleagues, 33 has recently been examined by Sanga and coworkers. 63 The authors applied the concept of using multicompartment pharmaco kinetics modeling to examine the effect of chemotherapy (e.g. cisplatin and doxorubicin) on tumor response. Their simulation results con firmed that the overall growth of a tumor mass depends to a considerable degree on the diffu sive distribution of nutrients, tissue pressure, and chemotherapeutic drugs.
Radiotherapy
In silico modeling has been applied in the area of radiotherapy for longer than in the field of chemotherapy. Kirkby et al. 64, 65 recently formu lated a brain tumor growth model for predicting survival in patients who have undergone radio therapy. More specifically, a stochastic modeling approach based on Monte Carlo methods was used to simulate a virtual population of 2,000 patients. These simulation data were then com pared with clinical data from 154 adult patients with GBM who received 60 Gy radiotherapy without adjuvant chemotherapy, that is, they were fitted to clinical survival data by minimizing the weighted sum of squares of errors between the simulated and real Kaplan-Meier survival curves. The results showed a close fit not only at early but also at later time points, when the simula tion data were able to reproduce the rather dismal outcome seen in the few longterm survivors. The authors go on to suggest that escalation of the radiotherapy dose to 74 Gy would increase overall survival time, as well as the proportion of patients who are longterm survivors.
This treatment 'recommendation' is in accor dance with the recommendation made by Dionysiou and coworkers, 66 who presented a 3D spatiotemporal model to simulate tumor cell repopulation, expansion and shrinkage. Their work focused also on the cancer cell cycle in the presence of radiotherapy, and a linear quadratic model that described the number of cells killed was developed. The results indicate that with regards to GBM control, a hyperfractionation scheme that delivers a total radiotherapy dose of 72 Gy in 6 weeks is superior to a standard frac tionation schedule that delivers only 60 Gy over the same time span. This finding was supported by the clinical studies cited by the authors, for example that of Fowler. 67 Recently, Stamatakos et al. 68 improved their earlier model by incorpo rating tumor vasculature and oxygen supply, as determined by imaging data. Comparing glioma eradication when using hyperfractionation and that when an accelerated hyperfractionation radiotherapy regimen was used, the model's predictions-including improved tumor control through hyperfractionation irradiation-were semiquantitatively in agreement with the clini cal findings reported by the Radiation Therapy Oncology Group Study 8302. 68 Future work on modeling aspects of cancer treatment should include studies that add an explicit molecular scale (such as relevant cell sig naling pathways), those that simulate the effects of therapy on the surrounding normal tissue, those that improve parameter values by using patientspecific data, and studies that systemati cally compare modeling predictions with clinical data obtained before, during, and after multi modality treatment.
FUTURe PeRSPeCTIveS
A review of selected neurooncology studies demonstrates that the field of in silico tumor modeling has indeed come a long way over the past r e v i e w www.nature.com/clinicalpractice/onc decade. Is in silico tumor modeling ready for prime time? The answer to this question depends largely on the deliverables, that is, what the modeling is supposed to achieve. Although there certainly is much reason for optimism, realistically, detailed and sufficiently accurate predictions that can reliably guide a patient's treatment might still be years away. The in silico generation of experimen tally testable hypotheses, however, is now a widely pursued interdisciplinary strategy in academic and industrial labs around the globe, where com putational modeling has also become an integral part of the elaborate drug discovery process. 63, 69 Moreover, few would argue that the integration of ever increasing yet disparate data can be achieved with anything but cutting edge computational modeling. As such, in silico modeling already is a key force in cancer research and is likely to find applications in the clinic in the near future.
Multiscale in silico modeling can yield valu able insights into the complex interactions of subcellular signaling networks and into how molecular perturbations penetrate throughout and across scales. The first and most critical step, however, is to decide on the scope of a model; this evolving aspect always entails a compro mise between model simplicity and thus tract ability, and the accuracy or biological relevance of a model. Ultimately, the scope of a model will depend on the biomedical questions under study and hypothesis posed. The same considerations will determine the choice of modeling tech nique and the approach taken; for example, 'topdown' or 'bottomup' . In contrast to most wetlab studies, in silico experiments can be per formed in a fast and relatively costefficient way, because it is possible to vary multiple parameters reproducibly and over a wide range when using this approach. In silico predictions can readily assist scientists in focusing laboratory studies, and eventually should aid clinicians in indivi dualizing patient treatment plans. The goal of any such patientspecific 'systems medicine' is to maximize effectiveness while minimizing nega tive adverse effects, an approach that would have obvious benefits for the individual patient as well as for the public healthcare system.
Although there are abundant potential edu cational applications in biomedical teaching and training, the real test of the relevance of in silico oncology-its quantitative application to and reliability in the clinical setting-is in its infancy 70 and several key obstacles will need to be tackled to move the field to the next level.
Firstly, in order to reduce inaccuracy as a result of estimating as yet unknown parameters, novel quantitative experimental techniques, such as phosphoproteomics and molecular imaging, 71 will need to make the transition into conven tional clinics, which will facilitate moreprecise parameterization of algorithms on the micro scopic-molecular interface. Hence, this shift will increase the models' predictive power and thus validity.
Secondly, on the computational side, a consid erable technical limitation is posed by the increas ing size of the current algorithms. Generally, the higher a model's spatial and temporal resolu tion, the higher is its compute power demand and thus the longer the run time of the code in a given information technology environment. For instance, although agentbased modeling has demonstrated considerable potential, the main drawback of this modality is the relatively intense compute power that is currently required in order to describe a cancer system at the level of its many constituent units and thus at a clinically relevant scale. Given the enormous amount of cancer data already collected and that we will have to deal with in the near future, parallelization of algorithm code for use in highperformance compute environments is likely to provide only a temporary solution; multiscale, multiresolution modeling seems a morepromising route. In this approach, compute power would be allocated to areas of the tumor model, and, at times, would likely have a substantial effect on the predictive power of a model, which requires close evaluation of simulation data and clinical data.
Finally, another important aspect of in silico modeling relates to improving the communica tion and interaction between in silico investigators and their experimental and clinical counter parts. In fact, access to raw data and exchange of expertise has been widely recognized as a criti cal obstacle that could hinder progress through out the field of life sciences. It is here where new efforts such as the Center for the Development of a Virtual Tumor 72 will have an important effect. Funded by the National Cancer Institute and charged with developing an online cancer model ing community and the innovative informa tion technology infrastructure to support it, the Center for the Development of a Virtual Tumor is poised to develop a semantic, digital model reposi tory that is geared towards facilitating retrieval, exchange and usage of cancermodelingrelated tools and data. 73 www.nature.com/clinicalpractice/onc
CONCLUSIONS
In summary, at the dawn of the era of cancer systems biology, computational and mathematical (i.e. in silico) modeling is and will continue to be an integral part of oncology. The in silico oncology field holds as much promise as it faces technical challenges, which must be resolved in order for the discipline to reach its true potential-that is, facilitating and accelerating the paradigmshifting transition from conventional populationbased approaches to patientspecific cancer medicine.
KeY POINTS
■
In generating experimentally testable hypotheses and facilitating multimodality data integration, in silico modeling is a driving force behind cancer systems biology ■ As exemplified by reviewing selected works on malignant brain tumors, practical applications for computational and mathematical cancer modeling reach from simulating aspects of tumor initiation and progression to modeling of treatment effect ■ In silico modeling is a tool geared to aiding experimental researchers and physicians in investigating the complex processes involved in tumorigenesis, thus supporting innovative discovery research and accelerating the identification of promising targets ■ Although there is no single simulator platform that fits all needs, discrete-continuum (hybrid) modeling, especially agent-based approaches, is particularly promising in integrating molecular, microscopic and macroscopic oncology data and in analyzing processes across scales in space and time
